Abstract
Treatment of inflammatory bowel disease (IBD) with antibodies against tumour necrosis factor-alpha (TNF) is effective. Not all patients respond, however, and the effect wears off in a considerable fraction of initial responders over time. Individual differences in bioavailability, pharmacokinetics and immunogenicity are now recognized as essential problems in the use of biologicals, and blood measurements of functional anti-TNF antibodies and antibodies against anti-TNF drugs with robust and clinically relevant methods may optimize treatment of IBD through individualized therapeutic regimens.
MeSH terms
-
Anti-Inflammatory Agents / blood
-
Anti-Inflammatory Agents / immunology
-
Anti-Inflammatory Agents / pharmacokinetics
-
Anti-Inflammatory Agents / therapeutic use*
-
Antibodies / blood
-
Antibodies, Monoclonal / blood
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / pharmacokinetics
-
Antibodies, Monoclonal / therapeutic use*
-
Biological Availability
-
Crohn Disease / blood
-
Crohn Disease / drug therapy
-
Crohn Disease / immunology
-
Drug Monitoring
-
Humans
-
Inflammatory Bowel Diseases / blood
-
Inflammatory Bowel Diseases / drug therapy*
-
Inflammatory Bowel Diseases / immunology
-
Infliximab
-
Precision Medicine
-
Time Factors
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
-
Tumor Necrosis Factor-alpha / immunology
Substances
-
Anti-Inflammatory Agents
-
Antibodies
-
Antibodies, Monoclonal
-
Tumor Necrosis Factor-alpha
-
Infliximab